The main focus of our research is to develop systematically administered, target-seeking therapeutic molecules for the regenerative medicine. These molecules would have two major benefits over the conventional therapeutics; their efficacy in the diseased organ would be enhanced due to the targeting while their side-effects would be simultaneously reduced in the normal, uninvolved organs. Our approach is based on two novel delivery mechanisms: A) building multi-functional fusion-proteins consisting of separate domains for targeting (and tissue penetration) and therapeutic effects and B) recently published revolutionary tissue-penetrating transport pathway, called “bystander effect”, to target the drugs without conjugating them to the delivery vehicle.
